Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.43 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.38 |
| ▸ | FEN1 | P39748 | 4/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 2/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3093233 | 0.80 | DPP4 (0.47) | TRPA1SCN2AALOX5APFEN1MET | |
| SCHEMBL30568360 | 0.71 | TRPA1 (0.49) | TRPA1IDO1 | |
| SCHEMBL21131387 | 0.71 | TRPA1 (0.49) | TRPA1IDO1 | |
| SCHEMBL3072112 | 0.68 | ALOX5AP (0.49) | TRPA1SCN2AALOX5APFEN1 | |
| SCHEMBL19927757 | 0.68 | ABL1 (0.44) | TRPA1ABL1BACE1 | |
| SCHEMBL29464972 | 0.68 | ABL1 (0.44) | TRPA1ABL1BACE1 | |
| SCHEMBL4018095 | 0.67 | PLAU (0.47) | ALOX5APFEN1MET | |
| SCHEMBL17963885 | 0.65 | BACE1 (0.36) | SCN2AALOX5APFEN1CYP17A1BACE1 | |
| SCHEMBL22117199 | 0.65 | BACE1 (0.43) | TRPA1BACE1 | |
| SCHEMBL3077316 | 0.64 | SCN2A (0.51) | SCN2AALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100227872-A1 | PYRAZINE DERIVATIVES | KEMP MARK IAN | 2010-09-09 | — | — | US | disclosed |
| EP-2155727-A1 | N-[6-AMINO-5-(PHENYL)PYRAZIN-2-YL]-ISOXAZOLE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS NAV1.8 CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | Pfizer Limited (GB) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008135830-A1 | N- [6-AMINO-S- (PHENYL) PYRAZIN-2-YL] -ISOXAZOLE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS NAV1.8 CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | PFIZER LIMITED (GB) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227872-A1 | PYRAZINE DERIVATIVES | CYP3A5, TRPV5, TRPV1 | TRPA1 9/4885SCN2A 150/4885ALOX5AP 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.